The EMERALD Trial: Comparing an Oral SERD vs. Endocrine Therapy for Advanced Breast Cancer

The EMERALD Trial: Comparing an Oral SERD vs. Endocrine Therapy for Advanced Breast Cancer

The EMERALD Trial: Comparing an Oral SERD vs. Endocrine Therapy for Advanced Breast Cancer
RestartResume

    How does a novel oral SERD compare to standard endocrine therapy for advanced breast cancer patients? Here’s what the EMERALD trial found.

    • Overview

      Endocrine therapy is the recommended treatment for ER+/HER2- advanced breast cancer, but progression to advanced disease can lead to ESR1 mutations, which can then lead to endocrine therapy resistance. But could treatment with an oral selective estrogen receptor degrader (SERD) improve outcomes for our patients? Join us as we take a deep dive into the EMERALD trial, which explored that exact question, in this Audio Abstract.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying Global Women's Health Academy…
    but how about a more personalized experience?

    Register for free